In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog GB-115 | Natural peptide Delta sleep-inducing peptide (DSIP) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Brain and mood | Brain and mood | |
| Evidence | |||
| Amount of evidence | 91 | 877 (plus 232 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 26 (14 in people) | 16 (8 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 2 · 1 active | None registered | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | GB-115 | Delta sleep-inducing peptide (DSIP) |
|---|---|---|
| Receptor activity and mechanismNervous system and cognition | 33 | 1167046 |
| NeuroprotectionNervous system and cognition |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
11 |
102102 |
| Anxiety and moodMental health and mood | 29524 | 31625 |
|---|
| Adverse eventsWhole body | 21138 | 1165 |
|---|
| Stress hormonesEndocrine and hormones | 11 | 448279 |
|---|
| PharmacokineticsPharmacology | 55 | 574017 |
|---|
| Cognition and memoryNervous system and cognition | 44 | 963 |
|---|
| Addiction, withdrawal and alcohol intakeMental health and mood | 33 | 981 |
|---|
| PainNervous system and cognition | 99 | 16115 |
|---|
| Inflammation markersImmune and inflammation | 55 | 14131 |
|---|
| Immune responseImmune and inflammation | 44 | 1212 |
|---|
| Exercise and physical functionWhole body | 211 | 77 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Valenta Pharm JSC250 participants13 Jan 2025 to est. 31 Dec 2027
Anxiety · Neurasthenia · Adjustment Disorders
Valenta Pharm JSC220 participants12 Oct 2022 to 3 Jan 2023
Anxiety · Neurasthenia · Adjustment Disorders
No registered trial that tests Delta sleep-inducing peptide (DSIP) found in ClinicalTrials.gov.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | GB-115 | Delta sleep-inducing peptide (DSIP) |
|---|---|---|
| Anxiety and moodMental health and moodCompared as: share of people in the arm that got the peptide, in % | 63.3% HARS responders Dose studied: 6 mg/day28 daysn = 2002026 | No randomized trial result 31 results from other study designs. |
| Adverse eventsWhole bodyCompared as: share of people in the arm that got the peptide, in % | 16% Patients with adverse events Dose studied: 6 mg/day28 daysn = 2002026 |
63.3%
HARS responders
Dose studied: 6 mg/day28 daysn = 2002026
No randomized trial result
31 results from other study designs.
No randomized trial result 11 results from other study designs. |
16%
Patients with adverse events
Dose studied: 6 mg/day28 daysn = 2002026
No randomized trial result
11 results from other study designs.